[CYTK] Cytokinetics, Incorporated

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 384.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 12.4 Change: 0.6 (5.08%)
Ext. hours: Change: 0 (0%)

chart CYTK

Refresh chart

Strongest Trends Summary For CYTK

CYTK is in the medium-term down -20% below S&P in 3 months and up 92% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a st

Fundamental Ratios
Shares Outstanding39.62 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -43.32% Sales Growth - Q/Q-79.71% P/E
P/E To EPS Growth P/S8.86 P/BV4.57 Price/Cash Per Share3.56
Price/Free Cash Flow-8.36 ROA-12.09% ROE-17.56% ROI
Current Ratio4.37 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-34.34% Net Profit Margin-34.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-32.09 M Cash From Operating Activities34.36 M Gross Profit
Net Profit-8.87 M Operating Profit-8.91 M Total Assets122.21 M Total Current Assets110.81 M
Total Current Liabilities25.39 M Total Debt Total Liabilities38.06 M Total Revenue4.41 M
Technical Data
High 52 week14.25 Low 52 week5.91 Last close11.6 Last change4.04%
RSI33.41 Average true range0.61 Beta1.31 Volume193.45 K
Simple moving average 20 days-2.21% Simple moving average 50 days-9.2% Simple moving average 200 days16.57%
Performance Data
Performance Week4.13% Performance Month-10.77% Performance Quart0% Performance Half39.59%
Performance Year27.47% Performance Year-to-date83.54% Volatility daily3.02% Volatility weekly6.75%
Volatility monthly13.83% Volatility yearly47.89% Relative Volume217.31% Average Volume449.52 K
New High New Low

News

2019-11-11 09:00:00 | Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019

2019-11-08 07:30:00 | Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes

2019-11-06 16:05:58 | Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes

2019-11-06 14:52:37 | Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT

2019-11-05 07:30:00 | Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference

2019-11-01 11:08:16 | Here is What Hedge Funds Really Think About Cytokinetics, Incorporated CYTK

2019-10-31 17:15:09 | Cytokinetics CYTK Reports Q3 Loss, Lags Revenue Estimates

2019-10-31 16:00:05 | Cytokinetics Reports Third Quarter 2019 Financial Results

2019-10-24 16:00:05 | Cytokinetics to Announce Third Quarter Results on October 31, 2019

2019-10-17 10:30:50 | Should You Worry About Cytokinetics, Incorporated's NASDAQ:CYTK CEO Pay?

2019-10-04 07:30:00 | Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting

2019-09-26 16:00:00 | Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting

2019-09-26 16:00:00 | Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

2019-09-25 07:30:00 | Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals

2019-09-23 05:54:09 | 3 Biotech Stocks Surging on Positive Results

2019-09-16 07:30:00 | Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23?? Annual Scientific Meeting

2019-09-06 16:00:00 | Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting

2019-09-03 16:00:00 | Cytokinetics to Present at September Investor Conferences

2019-09-02 13:00:18 | Is Cytokinetics NASDAQ:CYTK Using Too Much Debt?

2019-08-27 07:30:00 | Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

2019-08-09 03:08:01 | Edited Transcript of CYTK earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-09 01:23:47 | Cytokinetics Inc CYTK Q2 2019 Earnings Call Transcript

2019-08-08 20:30:12 | Cytokinetics CYTK Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 16:06:08 | Cytokinetics Reports Second Quarter 2019 Financial Results

2019-08-01 10:33:02 | Analysts Estimate Cytokinetics CYTK to Report a Decline in Earnings: What to Look Out for

2019-07-31 07:30:00 | Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions

2019-07-29 10:08:38 | Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more

2019-07-26 09:56:30 | Does Cytokinetics, Incorporated NASDAQ:CYTK Have A Volatile Share Price?

2019-07-25 16:28:37 | First big lease lands at Kilroy's huge Oyster Point project

2019-07-25 16:00:00 | Cytokinetics to Announce Second Quarter Results on August 8, 2019

2019-07-24 07:30:00 | Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics

2019-07-23 07:30:00 | Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy

2019-07-22 16:00:00 | Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions

2019-07-18 10:33:02 | Analysts Estimate Cytokinetics CYTK to Report a Decline in Earnings: What to Look Out for

2019-07-15 07:30:00 | Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

2019-06-28 07:30:00 | Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference

2019-06-27 13:29:10 | Did Hedge Funds Drop The Ball On Cytokinetics, Inc. CYTK ?

2019-06-24 16:00:00 | Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference

2019-06-13 14:40:35 | Could The Cytokinetics, Incorporated NASDAQ:CYTK Ownership Structure Tell Us Something Useful?

2019-06-12 16:00:00 | Cytokinetics to Present at the JMP Securities Life Sciences Conference

2019-05-30 07:30:00 | Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

2019-05-09 23:36:33 | Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 20:24:25 | Cytokinetics Inc CYTK Q1 2019 Earnings Call Transcript

2019-05-09 18:05:10 | Cytokinetics CYTK Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 16:54:27 | Cytokinetics: 1Q Earnings Snapshot

2019-05-09 16:00:00 | Cytokinetics Reports First Quarter 2019 Financial Results

2019-05-08 16:00:00 | Cytokinetics to Hold Annual Meeting of Stockholders

2019-05-06 10:29:15 | Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters

2019-05-06 09:18:00 | Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints

2019-05-05 13:11:00 | Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting